Rev-erbα, a component of the circadian clock, has also been known as a nuclear receptor that lacks activation function domain 2, functioning as a ligand-dependent transcriptional repressor. However, we recently reported that Rev-erbα activates connexin43 transcription by forming a complex with Sp1. Here we show that heme, a REV-ERB ligand, is dispensable for this novel mechanism and that Rev-erbβ, having homologies with Rev-erbα, does not activate connexin43, but competes with the Rev-erbα/Sp1. The A/B region of Rev-erbα, which is not conserved in Rev-erbβ, is a crucial activating domain, while the ligand binding domain, conserved in Rev-erbβ, functions as a competitor. Key words: Connexin43/Nuclear receptor/Rev-erbα/ Rev-erbβ /Sp1 Abbreviations: connexin43, Cx43; A/B region, AB, DNA binding domain, DBD; hinge region, H; ligand binding domain, LBD; Estrogen Receptor, ER Rev-erbα and Rev-erbβ, initially identified as orphan nuclear receptors Nr1d1 and Nr1d2, are also components of the circadian clock, have important roles in metabolism and cellular differentiation [1-4]. The circadian clock is genetic machinery that generates autonomous genetic oscillations in systemic organs by coordination of transcriptional activators (Bmal1 and Clock) and repressors (Per1-3 and Cry1, 2) that regulate other genes by binding to E boxes in promoter regions [5,6]. Concurrently, Rev-erbα/β and Rorα/β/ has been shown to tune the amplitude and the phase of the circadian clock, or control transcription of other non-clock genes, by binding to RORE sites of target genes [1,3,7,8].
INTRODUCTION

METHODS
Plasmid constructs. The mouse pGL-2-Cx43 promoter-reporter (pCx43 -1686/+165-luc), constructed by Dr. S.J. Lye [23] , was a kind gift from Dr. J. Yao (University of Yamanashi, Yamanashi, Japan). The pRL-TK (Promega, Madison, WI) were used as a transfection efficacy control. The Sp1 expression vector, constructed by Dr. Suske [24] was a kind gift from Dr. Toguchida (Frontier Medical Sciences, Kyoto University, Kyoto, Japan). The expression vector of Rev-erbα and Rev-erbβ was purchased from Open Biosystems (Huntsville, AL). Site-directed mutagenesis, deletion and addition of aimed sequences were performed using a mutagenesis basal kit (Takara) according to the manufacturer's protocol. These mutants were all verified by sequencing.
Promoter-reporter assay. Reporter plasmids with various expression vectors were transfected into HEK293T cells in 24-well plates using Fugene6 (Roche) in DMEM with 10% fetal calf serum (FCS) according to the manufacturer's protocol. pCx43-luc or pGL2-basic 100 ng and pTK-RL 5 ng were transfected with various amounts of expression vectors (total 250 ng). Plasmid dosage was kept constant by EGFP-N1 vector. Lysates were harvested 48 hours post-transfection, and the luciferase activity was measured using a dual luciferase assay reagent (Promega). For the hemin treatment, medium was changed to various concentration of hemin in DMEM with 10% FCS at 24 hour after the transfection and kept for 24 hour. For SR8278 (Sigma) and GSK4112 (Sigma) treatment, 24 hours after the transfection medium was changed to DMEM with 10% FCS containing 10M of each reagent and incubated for additional 24 hours.
Immunoblotting. Preparation of whole-cell lysates from HEK293T cells, and the immunoblotting procedure were performed as previously described [17, 25] . Briefly, cells were lysed in radio-immunoprecipitation assay (RIPA) buffer containing protease inhibitors. The protein content of the cell lysates was measured using the BioRad Protein Assay Kit. Cell lysates were resolved by sodium dodecyl sulfate polyacrylamide electrophoresis and transferred to an Immobilon-P membrane (Millipore, Bedford, MA).
The membranes were incubated with antibodies for Sp1 (Millipore, Milford MA, 
Co-immunoprecipitation assay.
Preparation of nuclear extracts and co-immunoprecipitation were performed as previously described [17] . Statistical analysis. We used one-way ANOVA followed by Tukey's post-hoc test for the multiple comparisons or by Dunnett's post-hoc test for comparing to the control in the promoter-reporter assay, calculated with SPSS ver.11.0.1J software (SPSS Inc., Chicago, IL). A P value < 0.05 was accepted as significant.
RESULTS AND DISCUSSION
Ligand is dispensable for activation by Rev-erbα with Sp1
Firstly, to investigate whether the transactivation of Cx43 promoter by Rev-erbα/Sp1 complex is controlled by heme, the ligand of Rev-erbα as a nuclear receptor, we applied various concentrations of heme to the HEK293T cells transfected with Rev-erbα/Sp1. Exogenously applied heme showed little impact on the Cx43 promoter activation ( Fig. 1A) , while it enhanced the suppressive effect on the abundance of Bmal1 protein as reported ( Fig. 1B) [13, 15] . In addition, SR8278, an antagonist of REV-ERB, was applied to block the action of endogenous agonist heme, which is always present in the cells [26] . It also had little effect on the Cx43 promoter activation, which was not influenced by addition of GSK4112, an agonist of REV-ERB ( Supplementary Fig. S1 ). Notably, although the ligand binding domain (LBD) of
Rev-erbα has been reported to be crucial for recruiting co-repressors [14, 15] , a deletion mutant of LBD of Rev-erbα (Rev ΔLBD) still retained transactivation activity for the Cx43 promoter (Fig. 1C) . In contrast to the suppressive effect of Rev-erbα, the ligand is not considered to play a significant role in the transactivation mechanism.
Rev-erbβ competes with Rev-erbα and Sp1 complex
Next, to investigate whether Rev-erbβ transactivates the Cx43 promoter in a similar manner as Rev-erbα with Sp1, we drove expression of Rev-erbβ in conjunction with a Cx43 promoter-reporter. However, Rev-erbβ scarcely affected the promoter activity of Cx43 even when co-expressed with Sp1 ( Fig. 2A) . Intriguingly, Rev-erbβ competed with Rev-erbα in the presence of Sp1 for the transactivation of the Cx43 promoter ( Fig. 2B) . This result is completely different from the previous notion that
Rev-erbα and Rev-erbβ have nearly identical functions in the liver [27] . These results prompted us to investigate the precise mechanism of Cx43 promoter transactivation by Rev-erbα with Sp1.
The A/B region of Rev-erbα is an activation domain.
Alignment comparison of Rev-erbα with Rev-erbβ disclosed that they have a different A/B region but a similar DNA binding domain (DBD), a hinge region (H) and a C terminal region of their LBD (Supplementary Fig. S2 ). According to their similarities and differences, we generated various domain oriented deletion mutants of Rev-erbα to examine the domains responsible for the activation of Cx43 (Fig. 3A) . The promoter-reporter assay revealed that, a part of the N terminal region of Rev-erbα (8-49) and the LBD were not crucial for the activation of the Cx43 promoter, while the A/B region, DBD and H region were indispensable (Fig. 3B) . These effects were also confirmed at the protein level by immunoblotting (Fig. 3C) . In accordance with previous reports [1, 14] , wild-type (WT) Rev-erbα successfully suppressed Bmal1 In light of these results, we focused on the A/B region as an activation domain and generated a DNA construct for expression of this region alone (HA-Rev AB).
Indeed, the HA-Rev AB still transactivated the Cx43 promoter transfected with Sp1 ( Fig. 3D ) and the HA-Rev AB was co-immunoprecipitated with Sp1 (Fig. 3E) .
The LBD of Rev-erbα is a competition domain.
Rev ΔAB, a mutant Rev-erbα without A/B region, not only failed to activate, but inhibited the transactivation of Cx43 promoter by Rev-erbα with Sp1 in a dose dependent manner (Fig. 4A) , indicating that Rev ΔAB contains a competition domain for Rev-erbα/Sp1 complex to transactivate the Cx43 promoter.
To identify the competition domain of Rev-erbα, we assessed the effect of Rev ΔH, Rev DBDLBD (a mutant of Rev-erbα only with the DBD and LBD) or Rev DBD (a mutant of Rev-erbα only with the DBD) with Rev-erbα/Sp1 (Supplementary Fig.   S3 ). The competition was observed in Rev ΔH and Rev DBDLBD but not in Rev DBD, indicating that not the H region or DBD but the LBD could be the required domain.
Indeed, Rev LBD (a mutant of Rev-erbα only with LBD) competed with the Rev-erbα/Sp1 (Fig. 4B) . Therefore, the LBD is involved in the transactivation of the Cx43 promoter by Rev-erbα/Sp1 complex as a potential competition domain.
Thus, different amino acid arrangements in the A/B activation domain regions of Rev-erbα and Rev-erbβ may underlie their differential activation of the Cx43 promoter. Conversely, high compatibility in LBD between these two Rev-erb subtypes may underlie the competitive effect of by Rev-erbα by Rev-erbβ (Fig. 4C) . We should note that this relationship between Rev-erbα and Rev-erbβ is similar to the relationship between Estrogen Receptor (ER) α and ERβ. The importance of the A/B region of nuclear receptors for associating with Sp1 has also been postulated for this ER family.
Saville and coworkers reported that the ERα possesses a transactivation function, but
ERβ does not, while a chimeric ERα/β, possessing the A/B region of ERα and other domains of ERβ, also has a transactivation function on a 17-beta Estradiol 2-responsive construct containing a GC-rich promoter [28] . ERα and ERβ are also competitive on the Sp1 site of the promoter [28] . Li and coworkers demonstrated that amino acids 67-139 of ERα, a part of the A/B region, were sufficient for the transactivation by ERα/Sp1 [29] .
The physiological implication of this novel competitive role for Rev-erbβ is unclear. Rev-erbβ is also a component of the circadian clock [27, 30] and oscillates in the urinary bladder (Supplementary Fig. S4) , thus one could speculate that Rev-erbβ tunes the circadian expression of Cx43 by competing with Rev-erbα. Because the peak expression of Rev-erbβ is 3.6 h later than Rev-erbα, followed by Cx43 ( Supplementary   Fig. S4 ) in the urinary bladder, Rev-erbβ may contribute to decrease the transactivation of Cx43 after the peak point. Since the present study relies to a large extent on overexpression and reporter assays, physiological relevance and functional significance of the findings still remains to be determined.
As other limitation of the present study, we showed the specific role of Rev-erbα domains for transactivation of the Cx43 promoter, but not the specific amino acid sequence required for the activation by Rev-erbα/Sp1 complex. The molecular structure of the complex, including the detailed interaction with Sp1 and other co-activators and/or co-repressors, which may also induce differences in effect of Rev-erbα/β [31] [32] [33] [34] , remains to be investigated to elucidate the entire mechanism of this novel transcription complex.
In summary, the present study shows that heme as the ligand is dispensable for transactivation of the Cx43 promoter by Rev-erbα with Sp1, and that the A/B region of Rev-erbα functions as an activation domain, while the LBD of Rev-erbα is a competition domain. This mechanism may underlie the competitive effect by Rev-erbβ on the transactivation. These findings provide a new insight into interaction between the clock regulator/nuclear receptors and Sp1. 
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